Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer

NCT02955290 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02955290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 22, 2016
Completion date
December 9, 2027
Enrollment
51 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced head and neck squamous cell carcinoma, advanced squamous non-small cell lung carcinoma, lung non-small cell carcinoma, metastatic lung non-small cell carcinoma, pd-l1 positive, recurrent head and neck squamous cell carcinoma, stage iii cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv cutaneous squamous cell carcinoma of the head and neck ajcc v8, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8, unresectable lung non-small cell carcinoma